Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.680
-0.010 (-0.37%)
At close: Dec 20, 2024, 4:00 PM
2.720
+0.040 (1.49%)
After-hours: Dec 20, 2024, 7:04 PM EST
Nuvation Bio Employees
Nuvation Bio had 51 employees as of December 31, 2023. The number of employees decreased by 2 or -3.77% compared to the previous year.
Employees
51
Change (1Y)
-2
Growth (1Y)
-3.77%
Revenue / Employee
$42,392
Profits / Employee
-$10,436,882
Market Cap
902.00M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51 | -2 | -3.77% |
Dec 31, 2022 | 53 | -11 | -17.19% |
Dec 31, 2021 | 64 | 28 | 77.78% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Aveanna Healthcare Holdings | 33,500 |
AMN Healthcare Services | 3,585 |
Phibro Animal Health | 1,940 |
Pacira BioSciences | 712 |
Adaptive Biotechnologies | 709 |
Cogent Biosciences | 164 |
ArriVent BioPharma | 40 |
NUVB News
- 1 day ago - Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration - PRNewsWire
- 25 days ago - Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
- 5 weeks ago - Nuvation Bio to Present at the Jefferies London Healthcare Conference - Business Wire
- 5 weeks ago - Top 4 Health Care Stocks That May Plunge This Quarter - Benzinga
- 6 weeks ago - Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer - Business Wire
- 3 months ago - Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - Business Wire
- 3 months ago - Nuvation Bio to Present at the Cantor Global Healthcare Conference - Business Wire